TCIM
AGIO icon

TIAA CREF Investment Management’s Agios Pharmaceuticals AGIO Stock Holding History

TIAA CREF Investment Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$10.7M Buy
158,029
+9,635
+6% +$561K 0.01% 1011
2018
Q4 		$6.84M Sell
148,394
-606
-0.4% -$37.4K 0.01% 1169
2018
Q3 		$11.5M Buy
149,000
+2,202
+2% +$177K 0.01% 1031
2018
Q2 		$12.4M Buy
146,798
+24,785
+20% +$2.16M 0.01% 1010
2018
Q1 		$9.98M Buy
122,013
+13,644
+13% +$1.05M 0.01% 1117
2017
Q4 		$6.2M Sell
108,369
-4,444
-4% -$280K ﹤0.01% 1475
2017
Q3 		$7.53M Sell
112,813
-4,452
-4% -$267K 0.01% 1340
2017
Q2 		$6.03M Buy
117,265
+28,030
+31% +$1.43M ﹤0.01% 1478
2017
Q1 		$5.21M Sell
89,235
-4,462
-5% -$214K ﹤0.01% 1570
2016
Q4 		$3.91M Buy
93,697
+9,285
+11% +$487K ﹤0.01% 1771
2016
Q3 		$4.46K Buy
84,412
+3,636
+5% +$158K ﹤0.01% 1679
2016
Q2 		$3.38M Buy
80,776
+5,852
+8% +$289K ﹤0.01% 1805
2016
Q1 		$3.04M Sell
74,924
-1,856
-2% -$79.3K ﹤0.01% 1842
2015
Q4 		$4.99M Sell
76,780
-100
-0.1% -$6.56K ﹤0.01% 1556
2015
Q3 		$5.43M Sell
76,880
-30,426
-28% -$2.97M ﹤0.01% 1481
2015
Q2 		$11.9M Buy
107,306
+58,305
+119% +$6.28M 0.01% 1032
2015
Q1 		$4.62M Buy
49,001
+850
+2% +$95.2K ﹤0.01% 1696
2014
Q4 		$5.39M Sell
48,151
-1,584
-3% -$141K ﹤0.01% 1580
2014
Q3 		$3.05M Sell
49,735
-1,072
-2% -$46.2K ﹤0.01% 1942
2014
Q2 		$2.33M Buy
50,807
+22,775
+81% +$928K ﹤0.01% 2218
2014
Q1 		$1.1M Hold
28,032
– – ﹤0.01% 2594
2013
Q4 		$671K Buy
28,032
+11,100
+66% +$253K ﹤0.01% 2874
2013
Q3 		$473K Buy
+16,932
New +$467K ﹤0.01% 2951

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

TIAA CREF Investment Management's AGIO Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Agios Pharmaceuticals (AGIO) stake by 6.5% in Q1 2019, buying an estimated $561K and bringing the position to 158,029 shares worth $10.7M. The position accounts for 0.01% of the portfolio, ranked #1011.

TIAA CREF Investment Management first reported a position in AGIO in Q3 2013 and has held it in 23 quarters since. The position peaked at $12.4M in Q2 2018. 201 funds tracked by Wall St. Rank hold AGIO as of Q1 2019.

  • TIAA CREF Investment Management held 158,029 shares of Agios Pharmaceuticals worth $10.7M as of Q1 2019.
  • TIAA CREF Investment Management bought 9,635 Agios Pharmaceuticals shares in Q1 2019, an estimated $561K.
  • Agios Pharmaceuticals made up 0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #1011 holding.
  • TIAA CREF Investment Management first reported a position in Agios Pharmaceuticals in Q3 2013 and has held it in 23 quarters since.
  • TIAA CREF Investment Management's Agios Pharmaceuticals position peaked at $12.4M in Q2 2018.
  • 201 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.